Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.

Abbisko Medicine Co., Ltd.
和譽醫藥有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER AND THE CHAIRMAN OF THE BOARD OF THE COMPANY

This announcement is made by Abbisko Medicine Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Directors**") of the Company was informed by Dr. Xu Yao-Chang ("**Dr. Xu**"), the founder, the executive Director, the chief executive officer of the Company and the chairman of the Board, that Dr. Xu purchased a total of 145,000 ordinary shares of the Company (the "**Shares**") in the open market on November 11, 2026 at an average price of approximately HK$6.67 per Share, representing approximately 0.02% of the total issued shares of the Company. Immediately following the purchase, Dr. Xu is interested in an aggregate of 81,747,574 Shares, representing approximately 11.26% of the total issued shares of the Company as at the date of this announcement.

As advised by Dr. Xu, he is confident about the business prospect and growth of the Group. Subject to applicable laws and regulatory requirements, Dr. Xu does not rule out the possibility that he may further increase his shareholding in the Company as and when appropriate.

Based on the information available to the Company and to the knowledge of the Board, following the completion of the increase in shareholding and as at the date of this announcement, the Company has maintained a sufficient public float of its issued shares in compliance with the applicable laws, rules and provisions, including the Rule 8.08 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"); and the increase in shareholding was conducted in compliance with the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 of the Listing Rules adopted by the Company. For the avoidance of doubt, Dr. Xu's purchase of the Company's shares on 11 November 2026 was made only after the Company had publicly disclosed the inside information regarding the FDA approval of PIMJETMI® (pimicotinib).

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Abbisko Medicine Co., Ltd.
Dr. Xu Yao-Chang
Chairman

Shanghai, November 11, 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.